Agenus | AGEN - Ordinary Share Capital


Agenus reported $35.32M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 35.32M 2.51M Dec/2025
Amgen USD 540M 1000K Mar/2026
AstraZeneca USD 1.55B 73K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.57M 20K Mar/2026
CSL USD 482.13M 93.87M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Intrexon USD 0 0 Jun/2024
J&J USD 2.41B 1.74M Dec/2025
Jiangsu Hengrui CNY 6.64B 0 Mar/2026
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
MacroGenics USD 63.32M 60K Dec/2025
Merck EUR 434.78M 0 Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Northwest Biotherapeutics USD 1.52B 1.52B Sep/2025
Novartis USD 1.91B 60K Mar/2026
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Veracyte USD 79.79M 743K Mar/2026